Lanean...
Immune checkpoint blockade in small cell lung cancer: is there a light at the end of the tunnel?
Small cell lung cancer (SCLC) is a very aggressive disease, characterised by rapid growth, high response rates to both chemotherapy and radiotherapy and subsequent development of treatment resistance in the vast majority of patients. In the past 30 years, little progress has been made in systemic tr...
Gorde:
| Argitaratua izan da: | ESMO Open |
|---|---|
| Egile Nagusiak: | , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BMJ Publishing Group
2016
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5070242/ https://ncbi.nlm.nih.gov/pubmed/27843619 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/esmoopen-2015-000022 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|